Eastman Chemical Management
Management criteria checks 2/4
Eastman Chemical's CEO is Mark Costa, appointed in Jan 2014, has a tenure of 12.33 years. total yearly compensation is $19.50M, comprised of 7.2% salary and 92.8% bonuses, including company stock and options. directly owns 0.44% of the company’s shares, worth $37.28M. The average tenure of the management team and the board of directors is 4.6 years and 10.3 years respectively.
Key information
Mark Costa
Chief executive officer
US$19.5m
Total compensation
| CEO salary percentage | 7.22% |
| CEO tenure | 12.3yrs |
| CEO ownership | 0.4% |
| Management average tenure | 4.6yrs |
| Board average tenure | 10.3yrs |
Recent management updates
Recent updates
Seeking Alpha • May 26
Eastman Chemical: Riding The Cycles To Shareholder Returns
Summary Eastman Chemical Company stands out as the top-quality option in the cyclical chemical sector, offering resilient dividend growth. EMN's U.S.-based assets provide insulation from geopolitical disruptions, enabling stable operations and pricing power amid sector volatility. EMN maintains a conservative payout ratio, supporting dividend growth even as peers like DOW and LYB cut dividends during downturns. Trading at an 11x forward PE, EMN offers potential for 22% total returns by 2027, with disciplined capital allocation and valuation awareness key to long-term success. Read the full article on Seeking AlphaAnalysis Article • May 09
Eastman Chemical's (NYSE:EMN) Soft Earnings Don't Show The Whole Picture
Eastman Chemical Company's ( NYSE:EMN ) stock was strong despite it releasing a soft earnings report last week. We...
Narrative Update • May 02
EMN: Supply Tightness And EV Glass Demand Will Support Earnings Recovery Potential
Analysts have made a modest upward adjustment to the Eastman Chemical price target to $96.01 from $95.39, reflecting updated views on the company following a mix of recent target hikes and one slight trim across major research firms. Analyst Commentary Recent Street research around Eastman Chemical has been active, with a cluster of price target changes and at least one upgrade, alongside a single modest trim.Narrative Update • Apr 18
EMN: Supply Tightness And Completed Buybacks Will Support Earnings Recovery Potential
Analysts have modestly raised their fair value estimate for Eastman Chemical to $95.39. This reflects updated price targets and recent research that points to slightly stronger revenue growth and profitability assumptions.
Narrative Update • Apr 04
EMN: Future Earnings Recovery Will Struggle With Persistent Commodity Oversupply
Analyst price targets for Eastman Chemical have shifted higher by several dollars into the mid $70s to mid $80s range, as analysts factor in updated commodity chemical forecasts, evolving geopolitical supply constraints, and a slightly adjusted risk profile reflected in modest tweaks to discount rate, revenue growth, profit margin, and future P/E assumptions. Analyst Commentary Street research on Eastman Chemical over recent months has featured a mix of higher price targets and recalibrated views on risk, as firms respond to commodity market forecasts, geopolitical bottlenecks in key shipping routes, and sector wide concerns around capacity and demand.Narrative Update • Mar 20
EMN: Supply Disruptions And Cash Returns Will Support Earnings Recovery Potential
Analysts nudged the fair value estimate for Eastman Chemical higher from $90.83 to $92.24, citing updated commodity chemical forecasts tied to supply disruptions and refined assumptions for revenue growth, profit margins, and future P/E multiples. Analyst Commentary Recent Street research on Eastman Chemical has leaned constructive, with several bullish analysts updating price targets and assumptions in response to both company specific factors and shifts in commodity markets.Narrative Update • Mar 05
EMN: Modest Upside As Oversupply And Deindustrialization Restrain Earnings Recovery Potential
Analysts have lifted their average price targets on Eastman Chemical by a mid single digit dollar range, with moves such as Evercore ISI taking its target to $75 from $70, as they factor in slightly different views on long term growth, profitability and valuation multiples, reflected in modest adjustments to revenue growth, profit margin, discount rate and future P/E assumptions. Analyst Commentary While several firms have nudged price targets higher on Eastman Chemical, there is also a thread of caution running through recent research that is worth keeping in mind when you think about risk and reward.Narrative Update • Feb 19
EMN: Cost Actions And Cash Returns Will Support Earnings Recovery Potential
Analysts have nudged their fair value estimate for Eastman Chemical up by about $1 to $90.83, pointing to refreshed assumptions around modestly positive revenue growth, a slightly lower discount rate, and a marginally reduced future P/E multiple as key drivers behind recent price target increases across the Street. Analyst Commentary Recent Street research shows a cluster of upward price target revisions for Eastman Chemical, even as some firms fine tune assumptions to reflect mixed end markets.Narrative Update • Feb 04
EMN: Oversupplied Commodity Markets Will Constrain Future Earnings Recovery Potential
Analysts have raised their fair value estimate for Eastman Chemical from $60.00 to $67.00. This reflects updated assumptions for revenue growth, profit margins, and a higher future P/E multiple, following a series of recent price target increases across the Street.Narrative Update • Jan 21
EMN: Cost Savings And Free Cash Flow Will Support Earnings Recovery Potential
Narrative Update Analysts have trimmed their consolidated price expectations for Eastman Chemical by around $1. They are factoring in softer revenue growth assumptions, slightly lower future P/E multiples, and a mixed set of recent target changes that balance cautious industry views with confidence in cash generation and margin resilience.Narrative Update • Jan 07
EMN: Cost Savings And Asset Utilization Will Drive Earnings Recovery Potential
Analysts have trimmed their fair value estimate for Eastman Chemical to about $90 from roughly $95, reflecting slightly higher discount rate assumptions and somewhat softer profit margin expectations. They still point to cost savings, asset utilization ramps and solid free cash flow as key supports for their updated price targets around $73 to $75.Analysis Article • Jan 05
These 4 Measures Indicate That Eastman Chemical (NYSE:EMN) Is Using Debt Extensively
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Narrative Update • Dec 23
EMN: Cost Savings And Asset Utilization Will Support Stronger Free Cash Flow
Analysts have nudged their average price target for Eastman Chemical slightly higher to about $73 from roughly $72.75, citing expectations for 2026 earnings tailwinds from cost savings, improved asset utilization, and resilient free cash flow even through a sluggish demand backdrop. Analyst Commentary Bullish analysts highlight that, despite modest adjustments to price targets, the long term investment case for Eastman Chemical remains underpinned by 2026 earnings tailwinds, including structural cost savings and improved asset utilization that are expected to drive margin expansion and profit growth from 2025 onward.Narrative Update • Dec 09
EMN: Cost Savings And Asset Utilization Will Drive Earnings Higher From 2025
Analysts have modestly trimmed their price target on Eastman Chemical by about $2 per share to approximately $74, citing a still challenging macro backdrop but highlighting improving 2026 earnings visibility driven by cost savings, asset utilization tailwinds, and the company’s ability to sustain solid free cash flow through the current earnings trough. Analyst Commentary Recent Street commentary reflects a generally constructive stance on Eastman Chemical, with price targets clustered in the low to mid 70s and Buy ratings maintained even as estimates and targets are adjusted to reflect a tougher macro environment.Narrative Update • Nov 25
EMN: Cost Savings And Asset Utilization Will Drive Earnings From 2025
The average analyst price target for Eastman Chemical has edged slightly lower to approximately $73, down less than $1, as analysts cite both resilient free cash flow and ongoing cost-saving initiatives in the context of a mixed demand outlook. Analyst Commentary Recent analyst updates reflect a nuanced perspective on Eastman Chemical's outlook, with both bullish and bearish takeaways emerging from the latest price target revisions and research commentary.Narrative Update • Nov 09
EMN: Cost Savings And Asset Utilization Will Drive Earnings Upside Ahead
Eastman Chemical's analyst price target was adjusted slightly downward by $1.53 to $73.06, as analysts cite a focus on cash generation and persistent end-market sluggishness, even though earnings improvements are expected ahead. Analyst Commentary Recent analyst updates on Eastman Chemical reflect a mix of cautious optimism and ongoing concerns related to the company's valuation and execution in a challenging market environment.Narrative Update • Oct 26
Commodity End Markets And Recycling Initiatives Will Shape Recovery Prospects Ahead
Eastman Chemical's analyst price target has been reduced by approximately $1 to $74.59. Analysts cite persistent macro headwinds and weakening conditions in commodity and industrial end markets as key factors behind this revised outlook.Narrative Update • Oct 12
Molecular Recycling And Specialty Materials Will Expand Global Reach
Analysts have lowered their price target for Eastman Chemical from $86 to $75, citing expectations of softer revenue growth and a moderately higher discount rate. Analyst Commentary Bullish Takeaways Bullish analysts continue to maintain a Buy rating on Eastman Chemical, citing confidence in the company's longer-term fundamentals.Analysis Article • Aug 02
Eastman Chemical Company (NYSE:EMN) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough
Eastman Chemical Company ( NYSE:EMN ) shareholders that were waiting for something to happen have been dealt a blow...Analysis Article • Jun 18
We Think Eastman Chemical (NYSE:EMN) Can Stay On Top Of Its Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Seeking Alpha • Jan 26
Following Up On A Correctly-Rated Eastman Chemical Company In 2025 (Rating Upgrade)
Summary Eastman Chemical has underperformed recently but shows promise with improved valuation and strategic direction, making it a conservative "Buy" for 2025. The company’s strong fundamentals, diverse product portfolio, and focus on sustainability, especially in molecular recycling, position it well for future growth. Despite recent declines, Eastman’s operational improvements, share buybacks, and favorable macro trends suggest significant upside potential, with expected earnings growth in the coming years. I rate Eastman Chemical a "Buy" at a valuation target of $140/share, anticipating a 15% annualized return based on a 12.2x P/E multiple. Read the full article on Seeking AlphaSeeking Alpha • Oct 14
Eastman Chemical: Difficult To See Upside At This Valuation (Rating Downgrade)
Summary Eastman Chemical Company has shown strong 2Q24 results, particularly in advanced materials, but its current valuation appears overvalued, leading to a “Hold” rating. The company's strategic focus on specialty products and de-commoditization, along with new assets, has improved margins and operational performance. Despite positive trends, macroeconomic pressures and weak underlying demand outside destocking pose challenges, with limited upside potential at the current valuation. Eastman Chemical remains a fundamentally sound and ESG-focused company, but better investment opportunities exist in the market, warranting caution. Read the full article on Seeking Alpha
New Narrative • Aug 22
Transforming Challenges Into Opportunities With Green Chemical Recycling And Innovative Growth
Expansion in sustainable solutions like chemical recycling and the Tritan product line indicates potential for revenue growth and market share increase.Seeking Alpha • Jul 10
Eastman Chemical Running In Place (Rating Downgrade)
Summary Eastman Chemical is a $11.1 billion market cap specialty chemicals company offering a 3.4% dividend. The company’s new focus is on molecular (plastic) recycling. It has just opened a plant in Tennessee and received a US government grant to build one in Texas. Eastman’s second-largest number of plants are in high-cost Europe (nine). However, it is geographically diversified with 16 US plants and several in Asia and Latin America. Read the full article on Seeking AlphaCEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$399m |
| Dec 31 2025 | US$19m | US$1m | US$474m |
| Sep 30 2025 | n/a | n/a | US$699m |
| Jun 30 2025 | n/a | n/a | US$832m |
| Mar 31 2025 | n/a | n/a | US$922m |
| Dec 31 2024 | US$16m | US$1m | US$905m |
| Sep 30 2024 | n/a | n/a | US$885m |
| Jun 30 2024 | n/a | n/a | US$883m |
| Mar 31 2024 | n/a | n/a | US$925m |
| Dec 31 2023 | US$18m | US$1m | US$894m |
| Sep 30 2023 | n/a | n/a | US$585m |
| Jun 30 2023 | n/a | n/a | US$708m |
| Mar 31 2023 | n/a | n/a | US$692m |
| Dec 31 2022 | US$17m | US$1m | US$793m |
| Sep 30 2022 | n/a | n/a | US$1b |
| Jun 30 2022 | n/a | n/a | US$1b |
| Mar 31 2022 | n/a | n/a | US$818m |
| Dec 31 2021 | US$18m | US$1m | US$857m |
| Sep 30 2021 | n/a | n/a | US$511m |
| Jun 30 2021 | n/a | n/a | US$321m |
| Mar 31 2021 | n/a | n/a | US$494m |
| Dec 31 2020 | US$14m | US$1m | US$478m |
| Sep 30 2020 | n/a | n/a | US$472m |
| Jun 30 2020 | n/a | n/a | US$577m |
| Mar 31 2020 | n/a | n/a | US$808m |
| Dec 31 2019 | US$15m | US$1m | US$759m |
Compensation vs Market: Mark's total compensation ($USD19.50M) is above average for companies of similar size in the US market ($USD8.38M).
Compensation vs Earnings: Mark's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
CEO
Mark Costa (59 yo)
12.3yrs
Tenure
US$19,498,966
Compensation
Mr. Mark J. Costa is Chairman & CEO of Eastman Chemical Texas City, Inc. Mr. Costa joined the Eastman Chemical Texas City, Inc. in 2006. Mr. Costa was Director at International Flavors & Fragrances Inc. si...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 12.3yrs | US$19.50m | 0.44% $ 37.3m | |
| CFO & Executive VP | 6.3yrs | US$5.46m | 0.057% $ 4.9m | |
| Executive VP & Chief Commercial Officer | 12.3yrs | US$6.10m | 0.088% $ 7.5m | |
| Executive VP of Additives & Functional Products | 3.6yrs | US$4.99m | 0.021% $ 1.8m | |
| VP, Chief Accounting Officer & Controller | 4.6yrs | no data | 0.0063% $ 536.5k | |
| EVP, CTO & Chief Sustainability Officer | less than a year | US$4.25m | 0.061% $ 5.2m | |
| Vice President of Investor Relations & Communications | 23.8yrs | no data | no data | |
| Senior VP | 1.7yrs | no data | no data | |
| Senior VP & Chief Human Resources Officer | 3yrs | no data | 0% $ 0 | |
| MD of EMEA Region & Global Procurement Director | no data | no data | no data | |
| Senior VP of Regions & Chief Supply Chain Officer | 4.9yrs | no data | 0.017% $ 1.4m | |
| Senior VP & Chief Manufacturing Officer | 1.3yrs | no data | no data |
4.6yrs
Average Tenure
56yo
Average Age
Experienced Management: EMN's management team is considered experienced (4.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 13yrs | US$19.50m | 0.44% $ 37.3m | |
| Independent Director | 2yrs | US$308.05k | 0.0029% $ 245.7k | |
| Independent Director | 10.3yrs | US$325.05k | 0.0083% $ 704.9k | |
| Independent Director | 22.7yrs | US$329.05k | 0.022% $ 1.9m | |
| Lead Independent DIrector | 15.3yrs | US$350.05k | 0.0083% $ 708.3k | |
| Independent Director | less than a year | US$102.56k | 0.0014% $ 119.0k | |
| Independent Director | 14.5yrs | US$326.05k | 0.017% $ 1.4m | |
| Independent Director | 15.3yrs | US$334.55k | 0.0086% $ 734.6k | |
| Independent Director | 3.8yrs | US$311.05k | 0.0096% $ 815.4k | |
| Independent Director | 7.8yrs | US$324.55k | 0.0025% $ 210.9k | |
| Independent Director | 3.3yrs | US$306.55k | 0.0027% $ 233.0k |
10.3yrs
Average Tenure
66yo
Average Age
Experienced Board: EMN's board of directors are seasoned and experienced ( 10.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/27 05:46 |
| End of Day Share Price | 2026/05/27 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Eastman Chemical Company is covered by 36 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sergey Vasnetsov | Barclays |
| Michael Leithead | Barclays |
| Paretosh Misra | Berenberg |